All News

The treatment combination of Imfinzi plus radiotherapy is “promising” for certain patients with NSCLC, according to preliminary findings from a trial.

“Integrative therapies can be utilized at any point along the cancer spectrum from diagnosis, throughout treatment and into survivorship,” an expert said.

With National Hereditary Cancer Week and National Previvor Day coming up at the end of the month, I sat down to write something about cancer advocacy and being the parent of a previvor.

Women who were previously treated for cancer during childhood with specific chemotherapy have a higher chance of becoming diagnosed with breast cancer.

Reblozyl for anemia in patients with an MDS subset demonstrated positive effects, compared with previous treatments, according to an MDS expert.

Treatment with perioperative Imfinzi plus neoadjuvant chemotherapy may improve surgery outcomes for patients with resectable non-small cell lung cancer.

A new phase 2b/3 trial was approved to study of S-pindolol benzoate to treat cachexia, a wasting disease associated with cancer.

If I could turn back time and speak to my newly diagnosed self, here's what I'd say!

Tanning beds cause an increased risk of skin cancer among young people — especially those who have a family history of skin cancer.

Oftentimes, I find myself realizing that the statistics related to my cancer diagnosis are like an elephant in the room.

Hematopoietic cell transplantation improved survival among high-risk genetic subgroups of patients with myelodysplastic syndrome, a recent study found.

After cancer and chemo, I tell myself all the time that nothing matters more than your health.

As part of its Speaking Out video series, CURE spoke with Hannah-Lise Schofield of the Children’s Hospital of Philadelphia about the psychosocial needs of young patients with cancer and their families as well as how those needs change over time.

As part of its Speaking Out video series, CURE spoke with Bruce L. Levine of the University of Pennsylvania Perelman School of Medicine about advancements in treatments for pediatric cancer.

As part of its Speaking Out video series, CURE spoke Bruce L. Levine of the University of Pennsylvania Perelman School of Medicine about CAR-T cell therapy, what it means for young patients with cancer and what new horizons it has revealed for treatment.

As part of its Speaking Out video series, CURE spoke with Tom Whitehead, co-founder and president of the Emily Whitehead Foundation, about the process of seeking treatment and what resources are available for young patients with cancer and their families.

The FDA approved Ojjaara for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anemia.

Currently, the Food and Drug Administration lists 119 drugs as being in short supply, including 25 cancer drugs.

Although I know I am not a scientist, and understand my cancer may take a lifetime, I contemplate why I ended up with too many copies of the HER2 gene.

As The Los Angeles Rams celebrate a cancer survivor and a 9/11 survivor reveals his fourth cancer diagnosis, this is what’s happening in the oncology space this week.

Adding Imfinzi the pre- and post-surgical treatment for patients with non-small cell lung cancer led to improved results, research showed.

Blenrep improves durability and provides meaningful response rates to patients with relapsed/refractory multiple myeloma, researchers found.

CURE asked ChatGPT itself to write an article on the benefits of ChatGPT and artificial intelligence for patients with cancer and survivors.

So many aftereffects occurred with my two cancers.

Using a device such as a Fitbit or Apple Watch can make a big difference for patients and doctors.

The three-drug combination of Tagrisso plus platinum-based chemotherapy and pemetrexed boosted outcomes for patients with EGFR-mutant advanced non-small cell lung cancer.

Data revealed promising results for the combination of Trodelvy and Keytruda as a first-line treatment for patients with metastatic non-small cell lung cancer.

Patients "need to be proactive" as they coordinate care between two diseases.